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Summary
Folic acid intake reduces the risk of neural tube 
defects (NTDs). Although the 677C-*T mutation in 
the 5,1O-methylenetetrahydrofoIate reductase 
(MTHFR) gene is a risk factor for NTDs, it only partly 
explains the elevated homocysteine levels in mothers 
of children with NTDs. We measured vitamin B12, 
folate and homocysteine in patients with spina bifida 
(SB), their parents, and in controls, to investigate 
which other enzymes of homocysteine metabolism 
might be defective. Because homozygosity for the 
677C-+T mutation causes decreased plasma folate 
and increased red-cell folate (RCF) and plasma homo­
cysteine levels, we excluded individuals homozygous 
for that mutation. The remaining SB patients and 
their parents still had lowered plasma folate and 
elevated total homocysteine levels, and a small subset 
had decreased vitamin B12 levels. Red-cell folate was
the same in all groups, suggesting that dietary folate 
intake and its uptake was normal. Risk of SB was 
increased at the 25th percentile of plasma folate and 
at the 75th percentile of homocysteine values in SB 
patients and their parents, and at the 5th and 25th 
percentiles of vitamin B12 in mothers with SB-affected 
offspring. This underlines the functional importance 
of homocysteine remethylation to methionine. There 
was no correlation between vitamin B12 and homo­
cysteine or RCF. In combination with the lowered 
plasma folate (80-90% 5-methyltetrahydrofolate), 
our data do not support a major involvement of 
methionine synthase in the aetiology of SB. Our data 
rather favour the involvement of genetic variation at 
loci coding for the formation of 5-methyltetrahy­
drofolate, such as MTHFR, methylenetetrahydrofolate 
dehydrogenase or serine hydroxymethyltransferase.
Introduction
Neural tube defects (NTDs) can arise from incom­
plete closure of the cranial part of the neural 
tube, resulting in anencephaly, or imperfect closure 
of the caudal part of the neural tube, resulting 
in spina bifida (SB). The clinical expression of this 
disability varies from mild to very severe abnormal-
ities, which can be lethal. The aetiology of NTD 
is considered to be multifactorial, i.e. the com­
bined action of defective genes and nutritional 
factors.
Recently, our group identified the first genetic risk 
factor for SB,1 i.e. the 677C—>T mutation in the
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5,10-methylenetetrahydrofolate reductase (MTHFR) 
gene. These findings were confirmed by others.2 
MTHFR catalyzes the formation of methyltetrahy- 
drofolate, which is a substrate in the homocys­
teine remethylation to methionine (Figure 1), 
Homozygosity for the 677C-*T mutation results in 
elevated homocysteine levels and a redistribution of 
folates, viz. elevated red-cell folate (RCF) and 
lowered plasma folate levels.1
Periconceptional folate administration reduces the 
NTD birth prevalence by 60-100%.3"8 Although the 
biochemical effects of the 677C—»T mutation can be 
corrected by folate therapy, this mutation can 
account at the most (after combining the genotype 
of the mother and child) for 25% of the observed 
protective effect of folate.1,9 Other defective enzymes 
may thus be present in the folate-dependent homo­
cysteine metabolism of family members (patients and 
their parents) with SB offspring.
We studied the RCF levels and the vitamin B12, 
folate and total homocysteine levels in plasma of SB 
patients and their parents, and compared them to 
the values in controls. Plasma folate is 80-90% 
5-methyltetrahydrofolate, the circulatory form of 
folate. The other folate derivatives are mainly inside 
the cell. Abnormal vitamin and homocysteine pat­
terns could suggest other defective enzymes involved 
in homocysteine metabolism (i.e. methionine syn­
thase, methylenetetrahydrofolate or serine hydroxy- 
methyltransferase) in these families with SB offspring, 
The 677C->-T mutation in the MTHFR gene leads to 
lowered plasma folate levels and elevated plasma 
homocysteine levels in individuals homozygous for 
this mutation,1,9 indicating the plausibility of this 
present approach. Because these abnormal folate 
and homocysteine levels would have confounded
the present investigation, these individuals were 
excluded from the study. Heterozygosity for the 
677C->T mutation does not affect the homocysteine 
and folate status of these individuals.1,9 Therefore we 
regarded individuals heterozygous for this common 
mutation and individuals with a 'wild-type' genotype 
as one group.
Methods
Families with SB offspring (SB patients and their 
parents) were recruited in collaboration with a Dutch 
society for patients with central nervous system 
defects and their parents (BOSK).1 The study group 
included 63 mothers (mean age 45.7, + SD 11.7 
years); 56 fathers (mean age 47.6 + 11.6 years) and 
55 of their children with SB (mean age 23.3 + 11.6 
years). Children younger than 3 years were excluded, 
as were individuals homozygous for the 677C~*T 
mutation in the MTHFR gene. The control group of 
95 unrelated Dutch individuals (23 men and 72 
women), with no history of SB (mean age 41.0, SD 
9.0 years) was recruited by public advertisement.10'11 
The study was approved by the ethics committee, 
and written informed consent was obtained.
Total homocysteine concentrations were measured 
in EDTA plasma.12 Folate and vitamin B12 levels of 
heparinized plasma, and folate levels in red blood 
cells, were determined by Dualcount Solid Phase 
Boil Radio assay (Diagnostic Products).13
Statistics
Because the distribution of the data was skewed, 
results are expressed as medians + range and as 
percentiles of the total. Crude odds ratios (OR) and
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Figure 1. A simplified scheme of folate-dependent homocysteine metabolism. Key enzymes are given. MS, methionine 
synthase; MTHFR, 5,10-methylenetetrahydrofolate reductase; MTHFD, 5,10-methylenetetrahydrofolate dehydrogenase; 
SHMT, serine hydroxymethyl transferase; CBS, cystathionine /?-synthase,
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95% CJs for various cut-off points, 5%, 25%, 75% 
and 95%, respectively, were calculated to estimate 
the relative risk of the different vitamin levels. The 
association between variables was measured by a 
Spearman's rank correlation test Statistical signific­
ance was tested by Wilcoxon Rank Sum-test p <  0.05 
was considered statistically significant p values were 
two-tailed.
Results
Virtually all individual vitamin B12, RCF, plasma 
folate and homocysteine levels of patients with SB 
and their parents were within the normal range. 
However, the median homocysteine values of 
patients with SB and their parents were significantly 
elevated when compared to controls, and the plasma 
folate levels of the patients and their fathers were 
significantly lower when compared to controls 
(Table 1). Median plasma vitamin B12 and RCF levels 
did not differ from control values. After subdividing 
into groups with different increasing vitamin and 
homocysteine levels (Figure 2a-d), some 30-45% of 
the family members had plasma folate levels 
belonging to the lowest category of the controls 
(Figure 2a). Almost 50-75% of the SB patients and 
their parents had homocysteine levels within the two 
highest homocysteine categories of controls 
(Figure 2b). Only a small subset of the family mem­
bers had decreased vitamin B12 levels (Figure 2c). 
The distribution of RCF values in families with SB 
offspring resembled that in the controls (Figure 2d).
The 5% and 25% cut-off points of plasma folate, 
RCF and vitamin B12 were 7.4 and 11.0 nmol/I, 323 
and 415 nmol/I and 127 and 200 pmol/I, respect­
ively. The 75% and 95% cut-off points of plasma 
homocysteine were 12.5 and 17.9 |imol/l. Table2 
shows the calculated crude ORs for these cut-off 
points of plasma folate, vitamin B12, and homocyst­
eine of mothers, fathers and SB patients vs. controls. 
W e observed a significantly increased risk for SB 
offspring at the 25th percentile of the plasma folate 
levels and at the 75th percentile of the plasma 
homocysteine levels in SB patients and their parents.
. At the 5th and 25th percentile of vitamin B12 levels, 
only mothers of a child with SB showed an increased 
risk of SB-affected offspring.
To score for associations between the different 
vitamins and homocysteine levels of family members 
and controls, we calculated the Spearman correlation 
coefficients (Table 3), Plasma folate correlated with 
RCF and showed an inverse correlation with total 
plasma homocysteine. There was no correlation 
between plasma or RCF with vitamin B12. 
Homocysteine levels of family members showed an 
inverse correlation with RCF levels. The vitamin B12 
levels of SB patients showed an inverse correlation 
with plasma homocysteine values, and the vitamin 
B12 levels of the fathers correlated with the RCF 
levels. No other correlations were observed.
Discussion
W e examined the levels of vitamin BUf folate and 
homocysteine in families with SB-affected offspring 
to elucidate possible alterations in their metabolism. 
The median plasma homocysteine levels of SB 
patients and their parents were significantly higher 
than in controls. SB patients and their fathers had 
significantly lower median plasma folate levels. This
Table 1 Vitamins and plasma homocysteine levels of patients with SB and their parents without individuals homozygous 
for the 677C->T mutation, compared to control levels
Vitamin Group n Median [range] P
Plasma folate Patients 47 10.0 [5.1-26.0] 0.00001
(nmol/I) Mothers 60 12.5 [6.4-52.0] 0.30
Fathers 51 12.0 [4.9-28.0] 0.012
Controls 94 14.0 [6.6-20.4]
&
Plasma homocysteine Patients 55 12.5 [6.1-23.3] 0.0002
(jutmol/l) Mothers 63 12.5 [4.0-20.7] 0.0001
Fathers 56 13.4 [7.5-25.7] 0,00001
Controls 95 10.1 [6.4-23.0] —
Plasma vitamin B12 Patients 48 275 [77-920] 0.55
(pmol/I) Mothers 60 245 [43-620] 0.25
Fathers 51 220 [81-430] 0.11
Controls 94 255 [64-580]
RCF (nmol/I) Patients 45 470 [230-990] 0.07
Mothers 57 540 [280-1200] 0.58
Fathers 49 520 [300-1100] 0.51
Controls 72 520 [280-1000]
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was not observed in the mothers, but after subdivid­
ing into different categories, the mothers also showed 
an significantly increased risk of SB-affected offspring 
at the 25th percentile of plasma folate. The median 
vitamin B12 levels were not decreased in SB family 
members, but after subdividing into different categor­
ies, the mothers of a child with SB had a increased 
risk of SB-affected offspring at the 5th and 25th 
percentiles. These findings support our previous 
hypothesis of a role for folate-dependent homocyst­
eine metabolism in the aetiology of SB.13
NTD may partly be caused by nutritional folate 
deficiencies.14,15 RCF is an indicator for the stored 
folate derivatives in the cell. Some studies have 
reported decreased RCF levels in mothers with NTD 
offspring, indicating a possible nutritional folate defi­
ciency in these individuals.16,17 In our study, the RCF 
levels of family members were comparable to those 
of controls, arguing against nutritional folate defi­
ciency or a defect in folate uptake in our study 
group. However, families with SB offspring may have 
higher nutritional folate requirements, due to a 
defective folate metabolism.15 Especially during preg­
nancy, a relatively mild biochemical defect in folate 
metabolism/ requiring a higher nutritional folate 
intake, may become of major importance. In our 
study group, additional folate intake would be over­
coming a metabolic folate deficiency than supple­
menting a nutritional folate deficiency.
Several studies suggest that methionine synthase 
(MS) might be involved in the aetiology of 
NTD.13,16,ia In the presence of vitamin B12, MS 
catalyzes the transmethylation of 5-methyltetra- 
hydrofolate and homocysteine to methionine and 
tetrahydrofolate (Figure 1). Therefore a MS or vitamin 
B12 deficiency should theoretically lead to increased 
plasma folate and plasma homocysteine, and possibly 
to decreased RCF levels, a combination not observed 
in the present study. Although a small subset of 
mothers with SB-affected offspring had decreased 
vitamin B12 levels, no correlations with homocysteine 
or folate were observed. Instead, decreased plasma 
folate and normal RCF levels were present in patients 
with SB and their parents. If the availability of 
vitamin B12 were inadequate, one would also expect 
to find a correlation of vitamin B12 with RCF and an 
inverse correlation of vitamin B12 with plasma folate, 
which was not observed (Table 3). These findings do 
not support the presence of reduced MS activity in 
the aetiology of SB in our study group.
Figure 2, Vitamin and plasma homocysteine values 
divided into 5-6 different categories and presented as 
percentages of the total number contained in each group, 
a Plasma folate in nmol/L b Total plasma homocysteine 
in j-Lmoi/I. c Plasma vitamin B12 in pmol/l. d Red-blood- 
ceii folate in nmol/l.
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Table 2 Odds ratios (OR) and 95% CIs at different cut-off points of families with SB offspring versus controls. The cut-off 
points of plasma folate, vitamin B12 and RCF are 5% and 25% and the cut-off points of plasma homocysteine are 75% and 95%
Vitamin Croup n 25/75% OR [Cl] 5/95% OR [Cl]
Plasma folate Patients 45 2.1 [1.5-3.1] 5.0 [1.7-15.1]
Mothers 60 1.4 [1.0-2,2] 1.2 [0.3-5.1]
Fathers 51 1.7 [1,1-2.5] 2.3 [0,6-8.2]
Homocysteine Patients 55 2.1 [1.4-3.3] 2.6 [0.8-8.8]
Mothers 63 2.1 [1.4-3,3] 0,8 [0.2-4.0]
Fathers 56 2.9 [1.9-4,3] 3.0 [0.9-9.7]
Vitamin B12 Patients 48 1.1 [0.7-1.9] 2.5 [0.7-8.7]
Mothers 60 1.2 [1.0-2.4] 3.9 [1.3-11.9]
Fathers 51 1.4 [0.8-2.2] 0.5 [0.1-4.0]
RCF Patients 45 1.2 [0.7-2.3] 2.1 [0,5-9.1]
Mothers 57 1.2 [0.7-2.1] 0.8 [0.1-4.9]
Fathers 49 0.6 [0.3-1.3] 0.5 [0.1-4.6]
Table 3 Correlation between folate, vitamin B12 and plasma homocysteine of SB patients and their parents, and controls. 
The correlations are represented by Spearman correlation coefficients,
Correlation Number of pairs Correlation coefficient p
Pa tieri ts
Plasma folate vs homocysteine 47 -0.43 0.002
red-cell folate 45 0.47 0.001
vitamin B12 47 0.02 NS
Homocysteine vs. red-cell folate 48 -0.33 0.02
vitamin B12 45 — 0.32 0,03
Vitamin B12 vs. 
Mothers
red-cell folate 45 0.29 NS
Plasma folate vs. homocysteine 60 “ 0.59 0.0001
red-cell folate 57 0.62 0.0001
vitamin B12 60 — 0.04 NS
Homocysteine vs. red-cell folate 57 -0.41 0.002
vitamin B12 60 -0.02 NS
Vitamin BT2 vs. 
Fathers
red-cell folate 57 0.01 NS
Plasma folate vs. homocysteine 50 -0.49 0.0001
red-cell folate 49 0.72 0.0001
vitamin B12 51 0.26 NS
Homocysteine vs. red-cell folate 48 0.31 0.03
vitamin B12 50 -0.18 NS
Vitamin B12 vs. 
Controls
red-cell folate 49 0.33 0.02
Plasma folate vs. homocysteine 94 -0.44 0.0001
red-cell folate 72 0.57 0.0001
vitamin B12 94 0.03 NS
Homocysteine vs. vitamin B12 94 -0.15 NS
red~celI folate 72 -0.03 NS
Vitamin B19 vs. red-cell folate 72 0.02 NS
Kirke etal. observed decreased RCF, plasma folate 
and vitamin B12 levels in mothers with NTD offspring. 
Because RCF levels of these mothers showed a 
correlation with vitamin B12, they concluded that MS 
function is directly or indirectly impaired in these 
mothers.18 Increased plasma folate levels would 
support this hypothesis, but they in fact observed
decreased plasma folate levels, which argues again 
their hypothesis.
The lower vitamin B12 levels in a small subset of 
family members may be due to reduced intake, or 
disturbed metabolism of vitamin B12, The lower 
plasma folate levels observed by us and others18 are 
probably not caused by folate malabsorption,19 so
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may reflect mutations in genes encoding the enzymes 
involved in the formation of 5-methyltetrahydro- 
folate. In this respect, next to MTHFR, methylene- 
tetrahydrofolate dehydrogenase and serine hydroxy- 
methyl transferase (Figure 1) are candidate enzymes.
Vitamin B12 as a cofactor, and 5-methyltetrahy- 
drofolate as a cosubstrate, are essential for the 
remethylation of homocysteine to methionine. 
Methionine can be activated by ATP to S- 
adenosylmethionine (AdoMet). AdoMet donates its 
methyl group in over a hundred different methyltrans- 
ferase-catalyzed reactions, including protein and 
DNA methyl at ion.20 Thus reduced availability of 
vitamin B12 and 5-methyltetrahydrofolate might cause 
AdoMet depletion. Our study shows the presence of 
elevated plasma total homocysteine levels in families 
with SB offspring, correlating with lowered plasma 
folate levels, indicating a reduced conversion of 
homocysteine to methionine. We recently showed 
that addition of methionine and even homocysteine 
to cultured rat embryos prevented the development 
of NTD.21 Both the lowered plasma folate in SB 
patients and their parents, and the lowered vitamin 
B12 levels in mothers with SB-affected offspring 
observed in the present study, could cause a lowered 
methionine and AdoMet availability. This in turn 
may disturb gene expression via reduced DNA 
methylation and/or other important methylation reac­
tions in the cells, interfering with the proper closure 
of the neural tube.
In conclusion, we found increased homocysteine 
and decreased plasma folate levels in SB patients 
and their parents, indicating defects in the enzymes 
involved in the synthesis of 5-methyltetrahydrofolate. 
Reduced function of MTHFR, methylenetetrahy- 
drofolate dehydrogenase and serine hydroxymethyl 
transferase may be involved in the aetiology of NTDs.
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